Search
Showing results for "Childhood interstitial lung disease "
Our work has identified a clinically relevant host-derived factor that may participate in shaping early events in the aetiology of CF respiratory disease
There is a marked shift in innate and adaptive immune responses in Chinese immigrants after living in a Western environment for several years
Fighting pseudomonas aeruginosa and nontypeable haemophilus influenzae biofilms with host defence peptide as a novel step forward in the treatment of
Human perinatal life is characterized by a period of extraordinary change during which newborns encounter abundant environmental stimuli and exposure to potential pathogens. To meet such challenges, the neonatal immune system is equipped with unique functional characteristics that adapt to changing conditions as development progresses across the early years of life, but the molecular characteristics of such adaptations remain poorly understood.
We recently reported that offspring of mice treated during pregnancy with the microbial-derived immunomodulator OM-85 manifest striking resistance to allergic airways inflammation, and localized the potential treatment target to fetal conventional dendritic cell (cDC) progenitors. Here, we profile maternal OM-85 treatment-associated transcriptomic signatures in fetal bone marrow, and identify a series of immunometabolic pathways which provide essential metabolites for accelerated myelopoiesis.
Neonatal dendritic cells generated form CD34+ cord blood progenitors have a higher inflammatory potential when exposed to viral than bacterial related stimuli
To show underlying mechanisms, we examined differences in T-cell gene expression in samples at birth and at 1 year in children with and without IgE allergy.
This study aimed to determine whether chronic, low-dose exposure to geogenic particulate matter <10μm diameter (PM10) exacerbates viral infections of the...
Cystic fibrosis (CF) researchers are working hard to progress phage therapy as an alternative treatment to antibiotics in people with CF who develop life-threatening lung infections.
In this review, we explore current knowledge and provide guidance as to when and how the inhaled route may be of value when treating patients whose tracheas are intubated